![Paul Herzich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul Herzich
Directeur Technique/Scientifique/R&D chez
SOLID BIOSCIENCES INC.
Fortune : 725 654 $ au 30/06/2026
Profil
Paul Herzich is currently Chief Technology Officer at Solid Biosciences, Inc. since 2022.
Formerly, Dr. Herzich was Director-CGMP & Senior Manager at Bamboo Therapeutics, Inc. from 2016 to 2018, Senior Director-Manufacturing at LogicBio Therapeutics, Inc. from 2018 to 2019, Vice President-CMC at BridgeBio Pharma, Inc. from 2020 to 2021, Chief Technology Officer at AavantiBio, Inc. from 2021 to 2022, and Head-TD Manufacturing at Csl Seqirus from 2007 to 2015.
Education includes undergraduate studies at Rutgers State University of New Jersey and an MBA from Poole College of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SOLID BIOSCIENCES INC. 0,07 % | 18/02/2026 | 72 638 ( 0,07 % ) | 725 654 $ | 30/06/2026 |
Postes actifs de Paul Herzich
| Sociétés | Poste | Début |
|---|---|---|
| SOLID BIOSCIENCES INC. | Directeur Technique/Scientifique/R&D | 01/12/2022 |
Anciens postes connus de Paul Herzich
| Sociétés | Poste | Fin |
|---|---|---|
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Directeur Technique/Scientifique/R&D | 01/12/2022 |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01/04/2021 |
| LOGICBIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2019 |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops gene therapies for rare neuromuscular and central nervous system diseases | Corporate Officer/Principal | 01/01/2018 |
Csl Seqirus
 Csl Seqirus BiotechnologyHealth Technology Manufactures influenza vaccine products | Corporate Officer/Principal | 01/07/2015 |
Formation de Paul Herzich
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
13
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops gene therapies for rare neuromuscular and central nervous system diseases | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines and therapies for bone metabolism, cardiology, neurology and rare diseases | Health Technology |
Solid Biosciences, Inc.
 Solid Biosciences, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops treatments through gene therapy for patients with duchenne disease | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Poole College of Management
 Poole College of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Health Technology |
Csl Seqirus
Csl Seqirus BiotechnologyHealth Technology Manufactures influenza vaccine products | Health Technology |
